Chris Grange leads the Immunohistochemistry (IHC) group at Cell Signaling Technology, a position he has held for the past four years. Over his 15 years with CST, Chris has played a key role in building the company’s portfolio of IHC-validated antibodies and launching its IHC-validated direct conjugate and chimeric product lines. He remains focused on expanding CST’s reagent options and ensuring researchers have reliable tools for their tissue-based assays.
